首页 | 本学科首页   官方微博 | 高级检索  
检索        

4种生物学因子对局部晚期乳腺癌新辅助化疗疗效评估的价值
引用本文:顾蓓,郭斌,石国建,李惠华,张洁.4种生物学因子对局部晚期乳腺癌新辅助化疗疗效评估的价值[J].解剖学报,2019,50(3):329-333.
作者姓名:顾蓓  郭斌  石国建  李惠华  张洁
作者单位:昆山市第二人民医院甲状腺乳腺外科,江苏昆山,215300;昆山市第二人民医院甲状腺乳腺外科,江苏昆山,215300;昆山市第二人民医院甲状腺乳腺外科,江苏昆山,215300;昆山市第二人民医院甲状腺乳腺外科,江苏昆山,215300;昆山市第二人民医院甲状腺乳腺外科,江苏昆山,215300
摘    要:目的探讨p53、ki67、nm23、表皮生长因子受体(EGFR)在局部晚期乳腺癌新辅助化疗疗效评估中的价值。方法选取2013年1月1日~2018年3月31日我院收治的局部晚期乳腺癌患者98例,检测新辅助化疗前后p53、ki67、nm23、EGFR的变化及其与临床疗效的关系。结果化疗后的p53、ki67、EGFR阳性表达均较化疗前降低,nm23阳性表达均较化疗前升高,差异均有统计学意义(P<0.05)。p53阳性者的有效率低于阴性者,差异有统计学意义(P<0.05);ki67、nm23阳性者的有效率均高于阴性者,差异均有统计学意义(P<0.05);EGFR阳性者与阴性者的有效率差异无统计学意义(P>0.05)。结论新辅助化疗能够显著改善局部晚期乳腺癌患者生物学因子p53、ki67、EGFR、nm23的表达,同时p53、ki67、nm23对评估化疗疗效具有一定价值。

关 键 词:乳腺癌  p53  KI67  NM23  表皮生长因子受体  新辅助化疗  
收稿时间:2018-05-29
修稿时间:2018-06-25

Value of four biological factors in the evaluation of neoadjuvant chemotherapy for locally advanced breast cancer
GU Bei GUO Bin,SHI Guo-jian LI Hui-hua ZHANG Jie.Value of four biological factors in the evaluation of neoadjuvant chemotherapy for locally advanced breast cancer[J].Acta Anatomica Sinica,2019,50(3):329-333.
Authors:GU Bei GUO Bin  SHI Guo-jian LI Hui-hua ZHANG Jie
Institution:Department of Thyroid Breast Surgery, the Second People’s Hospital of Kunshan, Jiangsu Kunshan 215300, China
Abstract:To explore the value of p53, Ki67, nm23 and epidermal growth factor receptor (EGFR) in the evaluation of the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer. Methods From January 1, 2013 to March 31, 2018, 98 cases of locally advanced breast cancer in our hospital were selected as the research subjects. The changes of p53, Ki67, nm23 and EGFR before and after neoadjuvant chemotherapy and their relationship with clinical efficacy were detected. Results The positive expression of p53, Ki67 and EGFR after chemotherapy were all lower than those before chemotherapy, and the positive expression of nm23 was higher than that before chemotherapy, the difference was statistically significant (P<0.05). The effective rate of p53 positive was lower than that of the negative ones, and the difference was statistically significant (P<0.05). The effective rates of Ki67 and nm23 positive were higher than that of negative ones, and the difference was statistically significant (P<0.05). There was no statistical difference in effective rate between the positive EGFR and negative ones (P>0.05). Conclusion Neoadjuvant chemotherapy can significantly improve the expression of biological factors p53, Ki67, EGFR and nm23 in locally advanced breast cancer patients, and p53, Ki67 and nm23 have certain value in evaluating the curative effect of chemotherapy.
Keywords:Breast cancer  p53  ki67  nm2  Epidermal growth factor receptor  Neoadjuvant chemotherapy  Human  
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《解剖学报》浏览原始摘要信息
点击此处可从《解剖学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号